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Abstract
Background: Anemia is a widespread public health problem associated with an increased risk of
morbidity and mortality, especially in pregnant women. This study examined the agreement
between a portable hemoglobin photometer and a laboratory analyzer in determining hemoglobin
level in pregnant women.
Methods: This study recruited 69 pregnant women in Tibet, China. Capillary blood samples were
taken to measure hemoglobin concentration using the hemoglobin photometer and the laboratory
analyzer. Limit of agreement, concordance and intraclass correlation coefficient were used to
evaluate the agreement. Laboratory measurement was considered as the standard reference
method. Sensitivity and specificity were calculated to assess the error in screening for anemia.
Results: Mean difference between the two methods was -2.1 g/l. wide 95% limits of agreement
were found (-22.6 g/l to 18.4 g/l). The intraclass correlation coefficient was 0.795, and concordance
correlation coefficient was 0.793. Sensitivity and specificity were 94.9% and 76.7% respectively.
Positive predictive value was 84.1%, and negative predictive value was 92.0%.
Conclusion: This hemoglobin photometer is not recommended for determining hemoglobin
concentration in pregnancy in a high altitude area.
Background
Anemia is a widespread public health problem associated
with an increased risk of morbidity and mortality, espe-
cially in pregnant women [1]. The global prevalence of
anemia in pregnant women and non-pregnant women is
41.8% and 30.2% respectively [2]. Anemia during preg-
nancy is a well-established risk factor for both the mother
and the fetus [3]. Hemoglobin assessments are relatively
precise and are used to screen individuals for anemia, to
assess the iron status of populations, and to evaluate
responses to nutritional interventions. The portable
hemoglobin meter (HemoCue) has been widely used in
recent years [4].
The unreliability of methods used to determine hemo-
globin will widen the distribution of hemoglobin values,
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and may bias the estimates of anemia and its health con-
sequences. Previous evaluations on the performance of
the HemoCue device have revealed conflicting results.
von Schienck et al. [5] and Morris et al. [6] found a high
accuracy with this device compared with standard labora-
tory methods. However, Chen [7], Rippmann [8] and
Neville [9] did not recommend this device in general prac-
tice.
Only a few well-documented validation studies have been
reported in pregnant women. Hudson-Thomas et al. [10]
conducted a study in pregnant women in Jamaica; how-
ever, limited information was reported. Only one valida-
tion study has been conducted at an altitude of about
1500 meters above sea level in Mexico [11]. However,
there is no information on the performance of the
HemoCue device when used at a higher altitude. There-
fore we conducted a study in pregnant women in Lhasa,
Tibet, to assess the agreement of this device with a labora-
tory hematology analyzer to determine hemoglobin con-
centration. We also evaluated the performance of this
device in anemia screening in this population.
Methods
Subjects and study setting
The Tibet Autonomous Region is located in southwest
China, and is often called the "Roof of the World" or the
"Third Pole". In Lhasa, the capital of Tibet, the average
altitude is about 3700 meters above sea level. Natural con-
ditions in this area are extremely harsh. With the rise in
elevation, the air pressure and oxygen content per cubic
meter of air is reduced, the atmospheric pressure and oxy-
gen content are approximately two-thirds of those at
lower levels. This study was conducted in a prefecture
level general hospital. Subjects were from the outpatient
unit of the Obstetrics and Gynecology department. Preg-
nant women who came for antenatal examinations con-
sented to take part in the study whereas the pregnant
women with serious diseases were excluded. This study is
approved by the Research Ethics Committee of Xi'an Jiao-
tong University College of Medicine.
Principle of Measurements
The HemoCue®B-Hemoglobin system (HemoCue AB,
Ängelholm, Sweden) consists of disposable microcuvettes
containing reagent in a dry form and a single purpose-
designed photometer. The reaction in the microcuvette is
a modified azide-methemoglobin reaction. Sodium deox-
ycholate haemolyses erythrocytes and hemoglobin is
released. Sodium nitrite converts hemoglobin to methe-
moglobin which, together with sodium azide, gives azide-
methemoglobin. The absorbance is measured at two
wavelengths (570 nm and 880 nm) in order to compen-
sate for turbidity in the sample. The Sysmex KX-21TM
(Sysmex Corporation, Kobe, Japan) is an automated
blood cell counter intended for in vitro diagnostic use in
clinical laboratories. It is a compact, fully automated
hematology analyzer with simultaneous analysis of 18
parameters in whole blood mode and capillary blood
mode. It measures the hemoglobin concentration using a
non-cyanide hemoglobin method (STROMA-
TOLYSERWH). The instrument has been proved to pro-
vide accurate and reliable results including hemoglobin
concentrations [12,13]. A quality control of the Sysmex
KX-21 was achieved before each day of experiments. The
instrument measured the control material and compared
the results with a normal range of value given by the man-
ufacturer for eight parameters. If the results are outside
this range, the apparatus needs to be calibrated.
The calibration procedure was achieved just before start of
this study and every month thereafter according to the
user guide. At least five samples of a healthy subject are
used. Hemoglobin concentrate (HGB) and hematocrit
(HCT) of the samples were determined using another cal-
ibrated apparatus for 3 times (norm DIN 58931 for HGB
and norm DIN 58933 for HCT). The blood samples are
then measured with the Sysmex KX-21. A new calibration
value was calculated and replaced the old one.
Data collection
A specially trained nurse interviewed the subjects and exe-
cuted the HemoCue Measurement. Firstly subjects were
asked to sign a consent form and complete a short ques-
tionnaire. Then capillary hemoglobin measurement was
performed using the HemoCue device according to the
manufacturer's instructions. Briefly, a lancet punctured
the middle finger of the right hand and a capillary blood
sample was taken, the third drop of blood was used to fill
the cuvette. When the cuvette was full, it was correctly
placed in the HemoCue device immediately. The nurse
was trained to conduct the procedure of sampling and
measurement. The HemoCue devices used were checked
with the device-specific, control cuvette every day. If the
value obtained deviated from the assigned value on the
control cuvette card more than 3 g/l, this device will be
replaced by another calibrated one. The measurement was
conducted in an office and a thermometer was used to
confirm the proper temperature (15–40 centigrade).
Shortly after this, another nurse led subjects to the hospi-
tal laboratory where a laboratory hematology measure-
ment of each subject's capillary blood was carried out
using a standard procedure. Capillary blood mode is used.
Fingertip puncture were made and blood sample were
attracted to a capillary pipe. Quality control was run on
the analyzers on a daily basis. The nurse was responsible
for collect the report of the laboratory measurement.BMC Public Health 2009, 9:228 http://www.biomedcentral.com/1471-2458/9/228
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Statistical Analysis
Agreement between the HemoCue device and the labora-
tory analyzer was assessed by the method of Bland and
Altman [14], where the mean difference and the standard
deviation of the differences between the HemoCue and
the laboratory hematology analyzer, and the limits of
agreement were calculated. Figures plotting difference
against the average were graphed as Bland and Altman rec-
ommended [14]. The laboratory measurement was con-
sidered the standard in this study, and linear regression
analysis was used to calculate the coefficient of determina-
tion and to estimate the error in the HemoCue measure-
ments. We used intraclass correlation coefficient (ICC)
and concordance correlation coefficient (CCC) to meas-
ure the agreement between the two methods. The ICC
measures the amount of overall data variance due to
between-subject variability, while the CCC is based on the
distance in the plane of each pair of data to the 45° line
through the origin [15]. We also calculated the prevalence
of anemia using the criteria of National Centers for Dis-
ease Control and Prevention of the United States (CDC)
and CDC altitude adjustment [16,17]. The cut-off point of
CDC anemia criteria for pregnancy is 110 g/l in both the
first and third trimester and 105 g/l in the second trimes-
ter. According to the CDC formula, adjusted hemoglobin
concentration at an altitude of 3700 meter will be 28.5 g/
l lower than the actual one. The sensitivity, specificity,
positive predictive value, negative predictive value and
kappa value were calculated to assess the performance of
the two methods in screening for anemia.
Data were entered into a Microsoft ACCESS database and
analysis was carried out using Stata 8.0 for Windows.
Results
This study was carried out between October 2006 and
October 2007, on 69 pregnant women. Five subjects
refused to participate in the project. Table 1 shows the
characteristics of the study participants.
The overall mean difference between the two measure-
ments was -2.1 g/l, differing significantly from zero with
wide 95% LOA. Figure 1 represents the LOA and individ-
ual differences. The 95% LOA were -22.6 g/l and 18.4 g/l,
thus the HemoCue may be 22.6 g/l below or 18.4 g/l
above the measurement using the laboratory haematol-
ogy analyzer. The 95% confidence intervals of the LOA
were 15.86 g/l to 20.87 g/l, and -25.08 g/l to -20.06 g/l. To
assess the trend in the relationship between the difference
and the mean, analyses of logarithmic transformed data
were carried out. As Figure 2 shows, the difference was
then -0.02 and the LOA were -0.20 and 0.15 on a loga-
rithm scale. The LOA then had to be related to the original
scale of measurement. When the antilog of these limits
were taken we obtained 0.82 and 1.16. These limits tell us
that for about 95% of cases, the HemoCue measurement
of hemoglobin will be between 0.82 and 1.16 times that
of the laboratory measurement. Thus, the HemoCue
measurement may differ from the laboratory measure-
ment by 18% below and 16% above. Fifteen (21.7%) of
the absolute values of the difference were above 10.0 g/l.
Five (7.2%) of the absolute values of the difference were
above 20.0 g/l. Fifty-one (73.9%) of the values measured
by the HemoCue were within 10% of the corresponding
values measured by the laboratory haematology analyzer.
Only thirty-six (53.6%) of the values measured by the
HemoCue were within 5% of the laboratory measure-
ments.
The Pearson correlation coefficient between the
HemoCue hemoglobin concentration and the laboratory
hemoglobin concentration was 0.82, and the coefficient
of determination was 0.66. The ICC was 0.795, with a
95% confidence interval of 0.690 to 0.868. The CCC was
0.793 (95% confidence interval: 0.710–0.977). These
results give a moderate agreement between the two meas-
urements.
When hemoglobin concentrations were altitude-adjusted
by the CDC method [17], the overall prevalence of ane-
mia was 68.3% using the HemoCue device and was
56.5% using the laboratory analyzer. The kappa value was
0.729, indicating a moderate agreement. The sensitivity
and specificity were 94.9% and 76.7%, respectively, the
positive predictive value was 84.1%, and the negative pre-
dictive value was 92%, considering the laboratory ana-
lyzer as the reference method.
Discussion
Anemia affects 40% of pregnant women worldwide [2],
and is detrimental to the health of mother and their fetus.
Hemoglobin concentration is used for detecting anemia
and also evaluating the gravity of this disorder. The use of
a laboratory hematology analyzer is problematic in
remote areas. Portable hemoglobin meters offer a rapid,
handy and inexpensive measurement of hemoglobin. In
addition, the finger puncture to allow capillary blood
sampling as an easy technique is less resource-intensive
Table 1: Summary statistics of characteristics of the 69 pregnant 
women
Mean Minimum Maximum SD
Age (year) 27.12 19 40 4.84
Gestational age (week) 33.70 5 42 9.50
HCHB1 (g/l) 126.35 55 163 18.02
LAHB2 (g/l) 128.45 78 162 14.84
HCHB1, the haemoglobin concentration measured by HemoCue®; 
LAHB2, the haemoglobin concentration measured by laboratory 
analyzer; SD, standard deviation.BMC Public Health 2009, 9:228 http://www.biomedcentral.com/1471-2458/9/228
Page 4 of 6
(page number not for citation purposes)
than vein puncture, and is more acceptable to patients
and the community. The present study evaluated the
agreement between the HemoCue device and a laboratory
hematology analyzer for capillary hemoglobin measure-
ment. This is the first validation study conducted in a high
altitude area, thus filling a gap in this area.
The 95% LOA in present study is much wider compared
to a study (-2.93 g/l and 3.38 g/l) carried out in infants in
Honduras [6] and a study (-3.7 g/l and 4.5 g/l) carried out
in patients undergoing aortic surgery [18]. However, sev-
eral studies have demonstrated a similar LOA to that
obtained in this study. Bhaskaram et al. demonstrated a
LOA of -33 g/l and 9 g/l in India [19]. Rippmann et al.
found a LOA of -6.0 g/l and 18.0 g/l in surgical blood sam-
ples [8], while a LOA of -18.0 g/l and 16.8 g/l in a study
by van de Louw et al. was obtained in patients gastrointes-
tinal bleeding in France [20].
In our study 21.7% of the absolute values of the difference
were above 10.0 g/l. These results are slightly poorer than
those reported in previous studies. Radtke et al. reported a
difference of greater than 10.0 g/l in 9% of samples from
unselected German blood donors [21], and in a study by
Rippmann et al. [8], and the figure is 17.9%. van de Louw
et al. found 21% of the difference was greater than 10.0 g/
l [20]. The results in our study and from the previous stud-
ies highlight the need for a pilot validity study before the
HemoCue device can be used in a particular population or
setting such as high altitude regions. The determination of
hemoglobin in capillary blood using the HemoCue device
was not accurate in our study, which was similar to valida-
tion studies in patients and blood donors. The result con-
sists with a study conducted in Mexico middle high
altitude area [11]. We therefore do not recommend this
device to measure capillary hemoglobin in pregnancy in
high altitude regions due to the discrepancies associated
with this device compared to the laboratory hematology
analyzer.
ICC and CCC are commonly used to evaluate agreement
between measurements. In our study the ICC was 0.795,
and the CCC was 0.793. These findings were similar or
slightly poorer than those reported in previous studies in
general settings [6,11,22]. These findings together with
the LOA, confirm that capillary hemoglobin determina-
tion using the HemoCue does not have an acceptable
agreement with capillary hemoglobin determination
using the laboratory hematology analyzer.
In a study in Indonesian mothers, Sari et al. reported a
sensitivity of 70.6% and a specificity of 97.5% in detecting
anemia [23]. Radtke et al. reported a sensitivity of 98.0%
and a specificity of 50.0% in screening blood donors [21],
and Sawant et al. found a sensitivity of 99.0% and a spe-
cificity of 45.0% in screening blood donors [22]. In
Difference versus average of Hb measured by HemoCue and the hematology analyzer Figure 1
Difference versus average of Hb measured by HemoCue and the hematology analyzer. Horizontal line represents 
mean difference; broken lines represent 95% limits of agreement. Hb, hemoglobin concentration; HCHB, the hemoglobin con-
centration measured by HemoCue®; LAHB, the hemoglobin concentration measured by laboratory analyzer.
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another study in Mexico, Neufeld et al. reported a sensitiv-
ity of 79% in detecting anemia in adults and 84% in chil-
dren, and a specificity of 97% and 93% [11], respectively.
In the present study, setting the laboratory analyzer as ref-
erence method, the sensitivity and specificity for anemia
screening were 94.9% and 76.7%, the positive predictive
value was 84.1% and the negative predictive value was
92.0%. These results are similar to or slightly better than
previous studies, and the results seem acceptable.
Several authors have pointed out that capillary blood
samples are more variable than venous blood samples
[6,7], which may partly explain the poor agreement
observed in our study. A shortcoming of this study is that
this study did not measure with both methods using the
same puncture. Disagreement may also be affected by the
quantity of capillary blood samples, although the only
one nurse who conducted the sampling and measurement
process had undergone strict trainings.
The sample size in our study meets the general recommen-
dations of Altman of at least 50 subjects in a methods
comparison study [24].
This study is the first to evaluate HemoCue device in the
determination of capillary blood hemoglobin in pregnant
women in a very high altitude area. We also obtained
detailed information on the agreement between the port-
able HemoCue and a laboratory analyzer on hemoglobin
levels in pregnancy. Due to poor acceptance among partic-
ipants, we were unable to obtain duplicate measurements
for both methods to assess the reliability of these meth-
ods. However, the laboratory analyzer has been reported
to perform very well in other published articles. Although
we obtained poor agreement between HemoCue device
and the laboratory analyzer for the determination of cap-
illary blood hemoglobin, we do not know whether the
high altitude in the study area contributed to this poor
agreement. This is a topic that needs investigation.
Conclusion
Capillary hemoglobin determination using the HemoCue
does not have an acceptable agreement with capillary
hemoglobin determination using the laboratory hematol-
ogy analyzer. We therefore do not recommend this device
to measure capillary hemoglobin in pregnancy in high
altitude regions.
Difference versus average of Hb measured by HemoCue and the hematology analyzer after logarithmic transformation Figure 2
Difference versus average of Hb measured by HemoCue and the hematology analyzer after logarithmic trans-
formation. Horizontal line represents mean difference; broken lines represent 95% limits of agreement. Hb, hemoglobin con-
centration; HCHB, the hemoglobin concentration measured by HemoCue®; LAHB, the hemoglobin concentration measured 
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